Get the Stockscreener App
13.63
2.10%
0.28
Upstream Bio Inc stock is traded at $13.63, with a volume of 399.32K.
It is up +2.10% in the last 24 hours and up +25.16% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$13.35
Open:
$13.52
24h Volume:
399.32K
Relative Volume:
0.98
Market Cap:
$733.21M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-10.61
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+27.15%
1M Performance:
+25.16%
6M Performance:
+31.18%
1Y Performance:
+0.00%
1-Day Range:
$12.74
$13.96
1-Week Range:
$10.54
$13.96
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
13.63 | 718.15M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio Inc (UPB) Stock: A Year of Highs and Lows - investchronicle.com
What drives Upstream Bio Inc. stock priceOutstanding trading profits - jammulinksnews.com
Upstream Bio Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com
Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com
J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛
how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser
Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser
Upstream Bio management to meet with Piper Sandler - TipRanks
What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews
Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks
Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener
Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener
Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com
Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq
Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire
Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener
Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):